PREVIOUS
✖
Haemophilia A gene therapy
March 5 , 2024
265 days
357
0
- India has conducted the first human clinical trial of gene therapy for ‘haemophilia A’ at Christian Medical College – Vellore.
- Hemophilia is a group of conditions that impact the blood’s ability to coagulate, or clot.
- Hemophilia occurs when an individual has low levels of certain proteins in the blood, known as clotting factors.
- Hemophilia A and hemophilia B are the two main types of hemophilia.
- Both conditions have similarities but are distinguishable by the genetic variation that causes the blood clotting problem.
- People living with hemophilia A have a genetic variation in the F8 gene, which is responsible for producing blood clotting factor VIII.
- Hemophilia B have a genetic alteration in the F9 gene, which results in the underproduction of blood clotting factor IX.
Leave a Reply
Your Comment is awaiting moderation.